Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2004-10-26
2008-11-11
Coleman, Brenda L. (Department: 1624)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
C544S280000
Reexamination Certificate
active
07449473
ABSTRACT:
Disclosed are novel compounds that are A2Badenosine receptor antagonists having the following structure:wherein R1and R2are independently chosen from hydrogen, optionally substituted alkyl, optionally substituted cycloalkyl, optionally substituted aryl, and optionally substituted heteroaryl, and R4is an optionally substituted heteroaryl moiety. The compounds of the invention are useful for treating various disease states, including asthma, chronic obstructive pulmonary disorder, pulmonary inflammation, emphysema, diabetic disorders, inflammatory gastrointestinal tract disorders, immunological/inflammatory disorders, cardiovascular diseases, neurological disorders, and diseases related to angiogenesis.
REFERENCES:
patent: 5593975 (1997-01-01), Cristalli
patent: 5714494 (1998-02-01), Connell et al.
patent: 6117878 (2000-09-01), Linden
patent: 6825349 (2004-11-01), Kalla et al.
patent: 2005/0020532 (2005-01-01), Elzein et al.
patent: 2005/0070558 (2005-03-01), Videl Juan et al.
patent: 0764647 (1997-03-01), None
patent: WO 01/94350 (2001-12-01), None
Stefanachi et. al. (Tetrahedron Letters, 2003, 44(10), 2121-2123).
Stefanachi, A et al., “Fast and Highly Efficient One-Pot Synthesis of 9-Deazaxanthines”;Tetrahedron Letters; Elsevier Science Publishers,—Amsterdam, NL, vol. 44, No. 10; Mar. 3, 2003, pp. 2121-2123, XP004410067.
Carotti, A. et al, “8-Substituted-9-Deazaxanthines as Adenosine Receptor Ligands: Design, Synthesis and Structure-affinity Relationships at A2B”;European Journal of Medicinal Chemistry, Editions Scientifique Elsevier, Paris, FR, vol. 39, No. 10, Oct. 2004, pp. 879-887, XP004584651.
Grahner, B., et al., “Synthesis and Structure-activity Relationships of Deazaxanthines: Analogs for Potent A1-and A2-Adenosine Receptor Antagonists”;Journal of Medicinal Chemistry, American Chemical Society, Washington, U.S.; vol. 37, No. 10, 1994, pp. 1526-1534, XP001093706.
Hayallah, A., et al., “1,8-Disubstituted Xanthine Derivatives” Synthesis of Potent A2B-Selective Adenosine Receptor Antagonists;Journal of Medicinal Chemistry, American Chemical Society; vol. 45, No. 7; 2002; pp. 1500-1510.
Elzein Elfatih
Kalla Rao
Li Xiaofen
Marquart Tim
Perry Thao
Coleman Brenda L.
CV Therapeutics Inc.
Hartrum J. Elin
Moore Susanna
LandOfFree
Substituted pyrrolo[3,2-d]pyrimidin-2,4-diones as A 2b... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Substituted pyrrolo[3,2-d]pyrimidin-2,4-diones as A 2b..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Substituted pyrrolo[3,2-d]pyrimidin-2,4-diones as A 2b... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4028418